Skip to main content
Top
Published in: Lung 6/2013

01-12-2013

Relationship Between Quantitative CT Metrics and Pulmonary Function in Combined Pulmonary Fibrosis and Emphysema

Authors: Katsutoshi Ando, Mitsuaki Sekiya, Kazunori Tobino, Kazuhisa Takahashi

Published in: Lung | Issue 6/2013

Login to get access

Abstract

Purpose

Combined pulmonary fibrosis and emphysema (CPFE) is increasingly recognized, as current reports of its clinical features show. To determine CPFE’s physiologic and radiologic features, we conducted quantitative assessment of computed tomography scans to compare with those of chronic obstructive pulmonary disease (COPD).

Methods

In 23 patients with CPFE and 42 patients with COPD, we measured the extent of emphysema (LAA %), parenchymal density, and total cross-sectional areas of pulmonary vessels smaller than 5 mm2 (%CSA <5) and 5–10 mm2 (%CSA 5–10).

Results

For CPFE, airflow was better, but diffusing capacity for carbon monoxide (DLCO) was worse than for COPD, whereas LAA % was similar for both groups. The %CSA <5 was greater but %CSA5–10 was less in CPFE than COPD. COPD involved a negative correlation between DLCO and LAA % at all lung sites; those factors correlated for CPFE only in the upper lobe (r = −0.535). In contrast, CPFE had a negative correlation between DLCO and parenchymal density in lower lobes (r = −0.453), but COPD showed no correlation in any such sections. In CPFE, no correlation was apparent between LAA in upper lobes and parenchymal density in lower lobes. The annual rate of FVC decline (−169.26 ml/year) in CPFE patients correlated with parenchymal density (r = −0.714).

Conclusions

In CPFE, fibrosis and emphysema apparently existed independently, but both correlate with and likely contribute to the disproportionate reduction in gas exchange. Our study also suggested that pulmonary fibrotic changes may be more important contributors than emphysema for disease progression.
Literature
1.
go back to reference Cottin V, Nunes H, Brillet PY et al (2005) Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26:586–593CrossRefPubMed Cottin V, Nunes H, Brillet PY et al (2005) Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 26:586–593CrossRefPubMed
2.
go back to reference Mejía M, Carrillo G, Rojas-Serrano J et al (2009) Idiopathic pulmonary fibrosis and emphysema decreased survival associated with severe pulmonary arterial hypertension. Chest 136:10–15CrossRefPubMed Mejía M, Carrillo G, Rojas-Serrano J et al (2009) Idiopathic pulmonary fibrosis and emphysema decreased survival associated with severe pulmonary arterial hypertension. Chest 136:10–15CrossRefPubMed
3.
go back to reference Kitaguchi Y, Fujimoto K, Hanaoka M et al (2010) Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 15:265–271CrossRefPubMed Kitaguchi Y, Fujimoto K, Hanaoka M et al (2010) Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 15:265–271CrossRefPubMed
4.
go back to reference Kurashima K, Takayanagi N, Tsuchiya N et al (2010) The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology 15:843–848CrossRefPubMed Kurashima K, Takayanagi N, Tsuchiya N et al (2010) The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology 15:843–848CrossRefPubMed
5.
go back to reference Chiba S, Ohta H, Abe K et al (2012) The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysema. Pulm Med 492960 Chiba S, Ohta H, Abe K et al (2012) The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysema. Pulm Med 492960
6.
go back to reference Austin JH, Muller NL, Colman N et al (1999) Diagnosis of disease of the chest. WB Saunders, Philadelphia, pp 2168–2263 Austin JH, Muller NL, Colman N et al (1999) Diagnosis of disease of the chest. WB Saunders, Philadelphia, pp 2168–2263
7.
go back to reference Thurlbeck WM, Muller NL (1994) Emphysema: definition, imaging, and quantification. AJR Am J Roentgenol 163:1017–1025CrossRefPubMed Thurlbeck WM, Muller NL (1994) Emphysema: definition, imaging, and quantification. AJR Am J Roentgenol 163:1017–1025CrossRefPubMed
8.
go back to reference Sakai N, Mishima M, Nishimura K, Itoh H, Kuno K (1994) An automated method to assess the distribution of low attenuation areas on chest CT scans in chronic pulmonary emphysema patients. Chest 106:1319–1325CrossRefPubMed Sakai N, Mishima M, Nishimura K, Itoh H, Kuno K (1994) An automated method to assess the distribution of low attenuation areas on chest CT scans in chronic pulmonary emphysema patients. Chest 106:1319–1325CrossRefPubMed
9.
go back to reference Mishima M, Hirai T, Itoh H et al (1999) Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 96:8829–8834PubMedCentralCrossRefPubMed Mishima M, Hirai T, Itoh H et al (1999) Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 96:8829–8834PubMedCentralCrossRefPubMed
10.
go back to reference Nakano Y, Sakai H, Muro S et al (1999) Comparison of low attenuation areas on computed tomographic scans between inner and outer segments of the lung in patients with chronic obstructive pulmonary disease: incidence and contribution to lung function. Thorax 54:384–389PubMedCentralCrossRefPubMed Nakano Y, Sakai H, Muro S et al (1999) Comparison of low attenuation areas on computed tomographic scans between inner and outer segments of the lung in patients with chronic obstructive pulmonary disease: incidence and contribution to lung function. Thorax 54:384–389PubMedCentralCrossRefPubMed
11.
go back to reference Matsuoka S, Washko GR, Yamashiro T et al (2010) Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 181:218–225PubMedCentralCrossRefPubMed Matsuoka S, Washko GR, Yamashiro T et al (2010) Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 181:218–225PubMedCentralCrossRefPubMed
12.
go back to reference Matsuoka S, Washko GR, Dransfield MT et al (2010) Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation. Acad Radiol 17:93–99PubMedCentralCrossRefPubMed Matsuoka S, Washko GR, Dransfield MT et al (2010) Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD: correlations with emphysema and airflow limitation. Acad Radiol 17:93–99PubMedCentralCrossRefPubMed
13.
go back to reference Uejima I, Matsuoka S, Yamashiro T, Yagihashi K, Kurihara Y, Nakajima Y (2011) Quantitative computed tomographic measurement of a cross-sectional area of a small pulmonary vessel in nonsmokers without airflow limitation. Jpn J Radiol 29:251–255CrossRefPubMed Uejima I, Matsuoka S, Yamashiro T, Yagihashi K, Kurihara Y, Nakajima Y (2011) Quantitative computed tomographic measurement of a cross-sectional area of a small pulmonary vessel in nonsmokers without airflow limitation. Jpn J Radiol 29:251–255CrossRefPubMed
14.
go back to reference Ando K, Tobino K, Kurihara M et al (2012) Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis. Eur J Radiol 81:3925–3930CrossRefPubMed Ando K, Tobino K, Kurihara M et al (2012) Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis. Eur J Radiol 81:3925–3930CrossRefPubMed
15.
go back to reference Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung and Blood Institute, World Health Organization, Bethesda Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung and Blood Institute, World Health Organization, Bethesda
16.
go back to reference Sharp DS (1993) Reference values for lung function in the Japanese: recording of normal lung function from 11 institutes in Japan. Jpn J Thoracic Dis 31:421–427 Sharp DS (1993) Reference values for lung function in the Japanese: recording of normal lung function from 11 institutes in Japan. Jpn J Thoracic Dis 31:421–427
17.
go back to reference Demedts M, Behr J, Buhl R et al (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229–2242CrossRefPubMed Demedts M, Behr J, Buhl R et al (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229–2242CrossRefPubMed
18.
go back to reference Taniguch H, Ebina M, Kondoh Y et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821–829CrossRef Taniguch H, Ebina M, Kondoh Y et al (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821–829CrossRef
19.
go back to reference Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087CrossRefPubMed Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087CrossRefPubMed
20.
go back to reference Santos S, Peinado VI, Ramirez J et al (2003) Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:1250–1256CrossRefPubMed Santos S, Peinado VI, Ramirez J et al (2003) Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:1250–1256CrossRefPubMed
21.
go back to reference Barr RG, Mesia-Vela S, Austin JH et al (2007) Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the emphysema and cancer action project (EMCAP) Study. Am J Respir Crit Care Med 176:1200–1207PubMedCentralCrossRefPubMed Barr RG, Mesia-Vela S, Austin JH et al (2007) Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the emphysema and cancer action project (EMCAP) Study. Am J Respir Crit Care Med 176:1200–1207PubMedCentralCrossRefPubMed
22.
go back to reference Farkas L, Gauldie J, Voelkel NF et al (2011) Pulmonary hypertension and idiopathic pulmonary fibrosis. Am J Cell Mol Biol 45:1–15CrossRef Farkas L, Gauldie J, Voelkel NF et al (2011) Pulmonary hypertension and idiopathic pulmonary fibrosis. Am J Cell Mol Biol 45:1–15CrossRef
23.
go back to reference Judge EP, Fabre A, Adamali HI et al (2012) Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 40:93–100CrossRefPubMed Judge EP, Fabre A, Adamali HI et al (2012) Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 40:93–100CrossRefPubMed
24.
go back to reference Ebina M, Shimizukawa M, Shibata et al (2004) Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169:1203–1208CrossRefPubMed Ebina M, Shimizukawa M, Shibata et al (2004) Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169:1203–1208CrossRefPubMed
25.
26.
go back to reference Cosgrove GP, Brown KK, Schiemann WP et al (2004) Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 170:242–251CrossRefPubMed Cosgrove GP, Brown KK, Schiemann WP et al (2004) Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 170:242–251CrossRefPubMed
Metadata
Title
Relationship Between Quantitative CT Metrics and Pulmonary Function in Combined Pulmonary Fibrosis and Emphysema
Authors
Katsutoshi Ando
Mitsuaki Sekiya
Kazunori Tobino
Kazuhisa Takahashi
Publication date
01-12-2013
Publisher
Springer US
Published in
Lung / Issue 6/2013
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9513-1

Other articles of this Issue 6/2013

Lung 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.